##  [Novartis therapy Gilenya™ reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows](/us-en/news/media-releases/novartis-therapy-gilenyatm-reduced-risk-ms-disability-progression-regardless-treatment-history-or-disease-severity-new-analysis-shows-0 "Novartis therapy Gilenya™ reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows") 

  Apr 11, 2011